What Research Use Only Means

Prefer to order by phone? Call (408) 208-2430 to complete your purchase — our team will confirm your items and process payment securely. Dismiss

Research Use Only is a use restriction, not a quality grade. Not for human or veterinary use.

“Research Use Only” is a use restriction. It is not a vibe, not a quality grade, and not a disclaimer you drop in a footer to cancel the rest of the page. On this site it means a specific set of facts about the material: it is sold for laboratory research, it is not sold as a drug or a dietary supplement, and it is not for human or veterinary use.

This page states that restriction in plain language for the GLP-1-class research peptides PureLab Performance stocks — retatrutide and tirzepatide — and for how the rest of the GLP-1 hub is written. It is not a lecture. It is not a wink. Research use only.

What RUO means here, in one paragraph

Material labelled Research Use Only on PureLab Performance is intended solely for laboratory research. It is not a drug as sold here. It is not a dietary supplement. It is not food. It is not for human use and not for veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease. It has not been approved by the FDA in the form sold on this site. No dosing or administration guidance is provided. Purchasers are expected to be 18 or older and qualified to handle research chemicals.

That is the whole restriction. The rest of this page is what those sentences do — and do not — cover.

Not a drug, as sold here

A molecule can exist in more than one regulatory object. Tirzepatide is an FDA-approved drug substance in specific branded prescription products (Mounjaro, Zepbound). The vial on the tirzepatide product page is not that object. It is bulk research material: no NDA covering this presentation, no pharmacy chain of custody, no prescribing information, no clinician in the loop. The approval that exists for named drug products does not travel with the sequence onto an RUO vial.

Retatrutide is further back. It is investigational. It is not approved by the FDA, the EMA, or any other regulator, for any indication, in any jurisdiction. Phase 3 topline results and a stated Q1 2027 BLA target are not an approval. A database check of Drugs@FDA for “retatrutide” returns no record; the same endpoint returns the expected NDAs for tirzepatide. That difference is the point.

Literature about either compound describes drug product under protocol. Jastreboff et al., *N Engl J Med* 2023, is a phase 2 trial of investigational retatrutide. The SURPASS and SURMOUNT papers describe approved-path tirzepatide. None of that literature is a description of the research reagent, and none of it is a reason to use the research reagent in a person. Phase 2 is not approval. An approved branded product is not this vial.

Not a supplement

Dietary supplements are a defined regulatory category with their own labelling and claims rules. A lyophilized research peptide is not a supplement. Calling it one does not make the restriction softer. It makes the statement false.

Not for human or veterinary use

Bodily introduction of this material into humans or animals is outside the intended use. Per-kilogram figures from animal models do not scale to humans, and nothing on this site should be read as implying that they do. In-vitro and laboratory animal research, where a protocol actually calls for it, is a different sentence from “for use in a person.”

This is a use statement, not a purity statement. A clean HPLC trace does not convert an RUO reagent into a medicine. A Certificate of Analysis documents what was measured in a lot. It does not write an indication.

What RUO is not

Not a quality claim. RUO does not mean “high grade,” “pharmaceutical grade,” or “better than the other listing.” Grade, if it means anything here, is the lot-level data: named lab, method, chromatographic purity, identity, content versus label claim, or a plain “pending.” Retatrutide lot fghe8m6 is a worked example of publishing the unflattering assay alongside the clean chromatogram. That is documentation. It is not a change of use.

Not a clinical exemption. There is no version of this sentence that means “for research, unless you have a protocol at home.”

Not the footer doing the work. Intended use is not a single line in 8-point type. Under the Federal Food, Drug, and Cosmetic Act, a product’s intended use is determined from the objective evidence — labelling, the website as a whole, promotional claims, and the circumstances of sale (see 21 CFR 201.128). FDA has said, in so many words, that it looks at that whole record. A Research Use Only strip does not cancel therapeutic-style claims, or a cart that reads as an injection kit.

The whole site, not the disclaimer

In March 2026 FDA issued warning letter 721806 to Gram Peptides after reviewing grampeptides.com. The products included retatrutide, tirzepatide, and “Bacteriostatic Water for Injection.” The site carried Research Use Only language. FDA still classified the products as unapproved new drugs. The evidence it quoted was on-page copy presented as product benefits, and the sale of bacteriostatic water alongside peptides that require reconstitution, which the agency treated as evidence of intended injection.

The useful fact is not the company name. The useful fact is the method: intended use is read from the whole site. Claims, product mix, and how solvents are framed sit in the same record as the disclaimer. This is why PureLab Performance pages in this cluster state receptor class and laboratory documentation, cite trial literature as literature with its actual limits, and do not provide administration instructions. GLP-1 peptide reconstitution and storage is concentration arithmetic and handling for laboratory solutions. It is not a how-to-inject.

We do not need a competitor’s mistakes to know that. We do need to be precise about why a footer is not a strategy.

Pending data does not change the restriction

Tirzepatide currently lists lot, chromatographic purity, label claim, and identity as certificate pending, laboratory Krause Analytical. Pending means the numbers are not on the page yet. It does not mean the material is for a different use while we wait. Retatrutide lot fghe8m6 has a completed report; the restriction is the same.

What this site will and will not do with the language

We will name the compound, the receptor class, the lot, the lab, the method, and the result — including 87.6% of label claim when that is the result.

We will cite published papers as papers, with phase, sample size, and the limit that they describe drug product under protocol.

We will not recast those papers as a reason to use the research reagent in a person. We will not imply a clinical benefit from a research listing. We will not treat “research” as a code for something else.

If a sentence on this site is ambiguous between laboratory documentation and human use, the laboratory reading is the intended one, and the sentence should be rewritten until that is the only available reading. That is an editorial rule, not a slogan.

Research Area

Popular Compounds